Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss
Several medical studies have found that people taking GLP-1 medications have an elevated risk for nonarteritic anterior ischemic optic neuropathy, or NAION.
Read the full story on MarketWatch → Opens the original article on www.marketwatch.comSummary aggregated from MarketWatch's public RSS feed. The full reporting belongs to MarketWatch — please read it on their site.